A prospective observational biomarker study for lung cancer immunotherapy

A prospective observational biomarker study for lung cancer immunotherapy - Immuno-Oncology Biomarker Study (LC-SCRUM-IBIS)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026425

Enrollment

1000

Registered

2017-03-06

Start date

2017-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with a pathologic diagnosis of lung cancer (either biopsy or cytological diagnosis); 2) Patients who are or will be enrolled in one of the 3 observational studies of LC-SCRUM-Japan, and at the same time, in whom fresh frozen sample + 10 slides of unstained preparation for genetic analysis and blood samples can be collected; and 3) Patients who consent in writing to take part in the Study.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
The incidence of expression of PD-L1 in lung cancer	—

Countries

Japan

Contacts

Public ContactKiyotaka Yoh

National Cancer Center Hospital East Department of Thoracic Oncology

kyoh@east.ncc.go.jp04-7133-1111

Outcome results